» Articles » PMID: 26773924

Differential Effects of GLP-1 Receptor Agonist on Foam Cell Formation in Monocytes Between Non-obese and Obese Subjects

Overview
Journal Metabolism
Specialty Endocrinology
Date 2016 Jan 17
PMID 26773924
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Monocytes/macrophages (Mϕ) transform into foam cells in the presence of oxidized-LDL (ox-LDL), releasing inflammatory mediators. The antiatherogenic role of a dipeptidyl peptidase-4 inhibitor is mediated, in part, through improving the unbalance of inflammatory (M1)/anti-inflammatory (M2) phenotypes in monocytes. In this study, we examined differential regulation of glucagon-like peptide-1 receptor (GLP-1R) signaling for antiatherogenesis in monocytes/Mϕ from normal-weight control subjects and obese patients.

Methods: We evaluated the effects of exendin-4 (Ex-4), a GLP-1R agonist, on ox-LDL-stimulated foam cell formation, M1/M2 cytokine production, and organelle change in primary monocytes from control subjects and obese patients and human monocytic THP-1-derived Mϕ as well.

Results: Here we report that Ex-4 suppressed foam cell formation and M1 cytokine expression and, interestingly, induced indicators of autophagy in ox-LDL-stimulated monocytes from control subjects. The suppressing effects on foam cell formation by Ex-4 were reversed by a cAMP inhibitor. In contrast to control subjects, Ex-4 did not induce indicators of autophagy, but did induce foam cell formation and M1 cytokine expression in monocytes from obese patients. GLP-1R expression level was comparable between control subjects and obese patients. The effects of Ex-4 on inducing indicators of autophagy and suppressing foam cell formation were observed in THP-1 Mϕ.

Conclusions: These data suggest that GLP-1R signaling induces autophagy, thereby suppressing foam cell formation in non-obese subjects. In obese patients, GLP-1R stimulation increased foam cell formation and IL-6, TNF-α, and IL-1β production. Such altered signaling in monocytes of obese patients may be involved in the development of atherosclerosis.

Citing Articles

Role of Incretin Mimetics in Cardiovascular Outcomes and Other Classical Cardiovascular Risk Factors beyond Obesity and Diabetes Mellitus in Nondiabetic Adults with Obesity: a Meta-analysis of Randomized Controlled Trials.

Kamarullah W, Pranata R, Wiramihardja S, Tiksnadi B Am J Cardiovasc Drugs. 2024; 25(2):203-229.

PMID: 39616304 DOI: 10.1007/s40256-024-00695-9.


Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes.

Cebi M, Yilmaz Y Front Immunol. 2024; 15:1445634.

PMID: 39148730 PMC: 11324455. DOI: 10.3389/fimmu.2024.1445634.


Impact of Glucagon-Like Peptide 1 Receptor Agonists on Biochemical Markers of the Initiation of Atherosclerotic Process.

Hachula M, Kosowski M, Ryl S, Basiak M, Okopien B Int J Mol Sci. 2024; 25(3).

PMID: 38339133 PMC: 10855444. DOI: 10.3390/ijms25031854.


Novel Antidiabetic Agents and Their Effects on Lipid Profile: A Single Shot for Several Cardiovascular Targets.

Piccirillo F, Mastroberardino S, Nusca A, Frau L, Guarino L, Napoli N Int J Mol Sci. 2023; 24(12).

PMID: 37373310 PMC: 10299555. DOI: 10.3390/ijms241210164.


Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes.

Patti A, Giglio R, Allotta A, Bruno A, Di Bella T, Pantea Stoian A Biomedicines. 2023; 11(5).

PMID: 37239033 PMC: 10216597. DOI: 10.3390/biomedicines11051362.